Differences in biomarkers and molecular pathways according to age for patients with HFrEF

Joao Pedro Ferreira*, Wouter Ouwerkerk, Bernadet T. Santema, Dirk J. van Veldhuisen, Chim C. Lang, Leong L. Ng, Stefan D. Anker, Kenneth Dickstein, Marco Metra, John G. F. Cleland, Samani J. Nilesh, Gerasimos Filippatos, Joseph-Pierre Aboumsallem, Rudolf A. de Boer, Sylwia Figarska, Iziah E. Sama, Adriaan A. Voors, Faiez Zannad

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

8 Citaten (Scopus)
36 Downloads (Pure)


Aims Elderly patients with heart failure with reduced ejection fraction (HFrEF) have worse prognosis and less often receive guideline-recommended therapies. We aim to better understand the underlying pathophysiological processes associated with ageing in HFrEF potentially leading to targeted therapies in this vulnerable population.

Methods and results From a panel of 363 cardiovascular biomarkers available in 1611 patients with HFrEF in the BIOSTAT-CHF index cohort and cross-validated in 823 patients in the BIOSTAT-CHF validation cohort, we tested which biomarkers were dysregulated in patients aged >75 vs.

Conclusions In elderly HFrEF patients, pathways associated with extra-cellular matrix organization, inflammatory processes, and tumour cell regulation were activated, while pathways associated with tumour proliferation functions were down-regulated. These findings may help in a better understanding of the ageing processes in HFrEF and identify potential therapeutic targets.



Originele taal-2English
Pagina's (van-tot)2228-2235
Aantal pagina's8
TijdschriftCardiovascular Research
Nummer van het tijdschrift10
StatusPublished - 1-sep.-2021

Citeer dit